Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 1–9 of 12 results

  • 93_6-b-Tetrahydrooripavine-Base
    Quick ViewSelect options

    6-β-Tetrahydrooripavine Base (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Impurity <span style="color: #000000;"><strong>CAS#</strong></span> 63732-74-1 <span style="color: #000000;"><strong>CDC#</strong></span> 51634-0990-**
    Quick ViewSelect options
  • 95_8-Hydroxyhydromorphone
    Quick ViewSelect options

    8-Hydroxyhydromorphone (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Impurity <span style="color: #000000;"><strong>CAS#</strong></span> 339525-94-9 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0988-**
    Quick ViewSelect options
  • 94_8,14-Dihydrooripavine-Base
    Quick ViewSelect options

    8,14-Dihydrooripavine Base (CII)

    $575.00 – $2,300.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Impurity <span style="color: #000000;"><strong>CAS#</strong></span> 873087-79-7 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0083-**
    Quick ViewSelect options
  • 96_Dihydromorphine-Base
    Quick ViewSelect options

    Dihydromorphine Base (CI)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Impurity, EP Impurity D <span style="color: #000000;"><strong>CAS#</strong></span> 509-60-4 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0987-**
    Quick ViewSelect options
  • 83_Hydromorphone-Hydrochloride
    Quick ViewSelect options

    Hydromorphone Hydrochloride (CII)

    $173.00 – $3,460.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 71-68-1 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0057-**
    Quick ViewSelect options
  • 98_Hydromorphone-N-Oxide
    Quick ViewSelect options

    Hydromorphone N-Oxide (CII)

    $1,150.00 – $4,600.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> EP Impurity B, USP Impurity <span style="color: #000000;"><strong>CAS#</strong></span> 109648-80-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0991-**
    Quick ViewSelect options
  • 99_Hyrdromorphone-Aldol-Dimer-HCl
    Quick ViewSelect options

    Hyrdromorphone Aldol Dimer HCl (CII)

    $4,750.00 – $19,000.00
    <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2191-**
    Quick ViewSelect options
  • 65_Morphine-Base
    Quick ViewSelect options

    Morphine Base (CII)

    $575.00 – $2,875.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 57-27-2 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0018-**
    Quick ViewSelect options
  • 101_Morphinone-Perchlorate
    Quick ViewSelect options

    Morphinone Perchlorate (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Compound A <span style="color: #000000;"><strong>CAS#</strong></span> 91265-67-7 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1001-**
    Quick ViewSelect options
  • 1
  • 2

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate